Roivant Sciences’ $200 Million Investment in Immunovant

Wachtell, Lipton, Rosen & Katz served as legal advisor to the special committee of the Immunovant board.Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now